-
2
-
-
51349163043
-
Bisphosphonates: Mechanism of action and role in clinical practice
-
Drake MT, Clarke BL, Khosla S, 2008 Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83: 1032-1045.
-
(2008)
Mayo Clin Proc
, vol.83
, pp. 1032-1045
-
-
Drake, M.T.1
Clarke, B.L.2
Khosla, S.3
-
3
-
-
0032766937
-
Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats
-
Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A, 1999 Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60: 68-73.
-
(1999)
Teratology
, vol.60
, pp. 68-73
-
-
Patlas, N.1
Golomb, G.2
Yaffe, P.3
Pinto, T.4
Breuer, E.5
Ornoy, A.6
-
4
-
-
0027284434
-
Effects of the bisphosphonate, alendronate, on parturition in the rat
-
Minsker DH, Manson JM, Peter CP, 1993 Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 121: 217-223.
-
(1993)
Toxicol Appl Pharmacol
, vol.121
, pp. 217-223
-
-
Minsker, D.H.1
Manson, J.M.2
Peter, C.P.3
-
5
-
-
0026509637
-
Reproduction toxicity studies with pamidronate
-
Graepel P, Bentley P, Fritz H, Miyamoto M, Slater SR, 1992 Reproduction toxicity studies with pamidronate. Arzneimittelforschung 42: 654-667.
-
(1992)
Arzneimittelforschung
, vol.42
, pp. 654-667
-
-
Graepel, P.1
Bentley, P.2
Fritz, H.3
Miyamoto, M.4
Slater, S.R.5
-
6
-
-
33749595622
-
The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment
-
Ornoy A, Wajnberg R, Diav-Citrin O, 2006 The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22: 578-579.
-
(2006)
Reprod Toxicol
, vol.22
, pp. 578-579
-
-
Ornoy, A.1
Wajnberg, R.2
Diav-Citrin, O.3
-
7
-
-
59849124507
-
Pregnancy outcome following in utero exposure to bisphosphonates
-
Levy S, Fayez I, Taguchi N, et al, 2009 Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44: 428-430.
-
(2009)
Bone
, vol.44
, pp. 428-430
-
-
Levy, S.1
Fayez, I.2
Taguchi, N.3
-
8
-
-
77952745140
-
Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age?
-
Losada I, Sartori L, Di Gianantonio E, Zen M, Clementi M, Doria A, 2010 Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age? Autoimmun Rev 9: 547-552.
-
(2010)
Autoimmun Rev
, vol.9
, pp. 547-552
-
-
Losada, I.1
Sartori, L.2
di Gianantonio, E.3
Zen, M.4
Clementi, M.5
Doria, A.6
-
9
-
-
33744953434
-
Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: A report of four cases
-
Chan B, Zacharin M, 2006 Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 91: 2017-2020.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 2017-2020
-
-
Chan, B.1
Zacharin, M.2
-
10
-
-
21344456854
-
Maternal and fetal outcome after long-term pamidronate treatment before conception: A report of two cases
-
Munns CF, Rauch F, Ward L, Glorieux FH, 2004 Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19: 1742-1745.
-
(2004)
J Bone Miner Res
, vol.19
, pp. 1742-1745
-
-
Munns, C.F.1
Rauch, F.2
Ward, L.3
Glorieux, F.H.4
-
11
-
-
77950959084
-
Maternal and fetal outcome after long-term bisphosphonate exposure before conception
-
Hassen-Zrour S, Korbaa W, Bejia I, Saidani Z, Bergaoui N, 2010 Maternal and fetal outcome after long-term bisphosphonate exposure before conception. Osteoporos Int 21: 709-710.
-
(2010)
Osteoporos Int
, vol.21
, pp. 709-710
-
-
Hassen-Zrour, S.1
Korbaa, W.2
Bejia, I.3
Saidani, Z.4
Bergaoui, N.5
-
12
-
-
0035878618
-
Osteoporosis and multiple pregnancy--a case report with positive outcome
-
Harsch IA, Hubner RH, Hahn EG, Hensen J, 2001 [Osteoporosis and multiple pregnancy--a case report with positive outcome]. Med Klin (Munich) 96: 402-407.
-
(2001)
Med Klin (Munich)
, vol.96
, pp. 402-407
-
-
Harsch, I.A.1
Hubner, R.H.2
Hahn, E.G.3
Hensen, J.4
-
13
-
-
34347395432
-
The effect of pregnancy on pre-existing osteopenia: A case report
-
Athimulam S, Chan P, Baker M, Nauta M, Yoong W, 2007 The effect of pregnancy on pre-existing osteopenia: a case report. Arch Gynecol Obstet 276: 175-177.
-
(2007)
Arch Gynecol Obstet
, vol.276
, pp. 175-177
-
-
Athimulam, S.1
Chan, P.2
Baker, M.3
Nauta, M.4
Yoong, W.5
-
14
-
-
84863525145
-
Pregnancy-associated spinal osteoporosis treated with bisphosphonates: Long-term follow-up of maternal and infants outcome
-
in press
-
Vujasinovic-Stupar N, Pejnovic N, Markovic L, Zlatanovic M, 2011 Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome. Rheumatol Int, in press.
-
(2011)
Rheumatol Int
-
-
Vujasinovic-Stupar, N.1
Pejnovic, N.2
Markovic, L.3
Zlatanovic, M.4
-
15
-
-
34548437078
-
Maternal and fetal outcome of pamidronate treatment before conception: A case report
-
Cabar FR, Nomura RM, Zugaib M, 2007 Maternal and fetal outcome of pamidronate treatment before conception: a case report. Clin Exp Rheumatol 25: 344-345.
-
(2007)
Clin Exp Rheumatol
, vol.25
, pp. 344-345
-
-
Cabar, F.R.1
Nomura, R.M.2
Zugaib, M.3
-
17
-
-
78149409812
-
Intravenous bisphosphonate treatment and pregnancy: Its effects on mother and infant bone health
-
Mastaglia SR, Watman NP, Oliveri B, 2010 Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health. Osteoporos Int 21: 1959-1962.
-
(2010)
Osteoporos Int
, vol.21
, pp. 1959-1962
-
-
Mastaglia, S.R.1
Watman, N.P.2
Oliveri, B.3
-
19
-
-
0025187606
-
Antenatal administration of aminopropylidene diphosphonate
-
Dunlop DJ, Soukop M, McEwan HP, 1990 Antenatal administration of aminopropylidene diphosphonate. Ann Rheum Dis 49: 955.
-
(1990)
Ann Rheum Dis
, vol.49
, pp. 955
-
-
Dunlop, D.J.1
Soukop, M.2
McEwan, H.P.3
-
20
-
-
0029789509
-
Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate
-
Illidge TM, Hussey M, Godden CW, 1996 Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 8: 257-258.
-
(1996)
Clin Oncol (R Coll Radiol)
, vol.8
, pp. 257-258
-
-
Illidge, T.M.1
Hussey, M.2
Godden, C.W.3
-
21
-
-
4644310824
-
Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer
-
Andreadis C, Charalampidou M, Diamantopoulos N, Chouchos N, Mouratidou D, 2004 Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer. Gynecol Oncol 95: 252-255.
-
(2004)
Gynecol Oncol
, vol.95
, pp. 252-255
-
-
Andreadis, C.1
Charalampidou, M.2
Diamantopoulos, N.3
Chouchos, N.4
Mouratidou, D.5
-
22
-
-
33748105239
-
Malignant hypercalcemia in pregnancy: Effect of pamidronate on uterine contractions
-
Culbert EC, Schfirin BS, 2006 Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. Obstet Gynecol 108: 789-791.
-
(2006)
Obstet Gynecol
, vol.108
, pp. 789-791
-
-
Culbert, E.C.1
Schfirin, B.S.2
-
23
-
-
0033815510
-
Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding
-
Siminoski K, Fitzgerald AA, Flesch G, Gross MS, 2000 Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res 15: 2052-2055.
-
(2000)
J Bone Miner Res
, vol.15
, pp. 2052-2055
-
-
Siminoski, K.1
Fitzgerald, A.A.2
Flesch, G.3
Gross, M.S.4
-
24
-
-
0023948462
-
Absorbed dose to the fetus during bone scintigraphy
-
Hedrick WR, DiSimone RN, Wolf BH, Langer A, 1998 Absorbed dose to the fetus during bone scintigraphy. Radiology 168: 245-248.
-
(1998)
Radiology
, vol.168
, pp. 245-248
-
-
Hedrick, W.R.1
Disimone, R.N.2
Wolf, B.H.3
Langer, A.4
-
25
-
-
0022883887
-
Incidental diagnosis of pregnancy on bone and gallium scintigraphy
-
Palestro CJ, Malat J, Collica CJ, Richman AH, 1986 Incidental diagnosis of pregnancy on bone and gallium scintigraphy. J Nucl Med 27: 370-372.
-
(1986)
J Nucl Med
, vol.27
, pp. 370-372
-
-
Palestro, C.J.1
Malat, J.2
Collica, C.J.3
Richman, A.H.4
-
26
-
-
0027992077
-
Technetium-99m-methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation
-
McKenzie AF, Budd RS, Yang C, Shapiro B, Hicks RJ, 1994 Technetium-99m-methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation. J Nucl Med 35: 1338-1341.
-
(1994)
J Nucl Med
, vol.35
, pp. 1338-1341
-
-
McKenzie, A.F.1
Budd, R.S.2
Yang, C.3
Shapiro, B.4
Hicks, R.J.5
-
27
-
-
0034009975
-
A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy
-
Black AJ, Topping J, Durham B, Farquharson RG, Fraser WD, 2000 A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res 15: 557-563.
-
(2000)
J Bone Miner Res
, vol.15
, pp. 557-563
-
-
Black, A.J.1
Topping, J.2
Durham, B.3
Farquharson, R.G.4
Fraser, W.D.5
-
29
-
-
33646089442
-
Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite
-
Nancollas GH, Tang R, Phipps RJ, et al, 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38: 617-627.
-
(2006)
Bone
, vol.38
, pp. 617-627
-
-
Nancollas, G.H.1
Tang, R.2
Phipps, R.J.3
-
30
-
-
0035146537
-
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
-
Dunford JE, Thompson K, Coxon FP, et al, 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235-242.
-
(2001)
J Pharmacol Exp Ther
, vol.296
, pp. 235-242
-
-
Dunford, J.E.1
Thompson, K.2
Coxon, F.P.3
-
31
-
-
0029886359
-
Bisphosphonates: A review of their pharmacokinetic properties
-
Lin JH, 1996 Bisphosphonates: a review of their pharmacokinetic properties. Bone 18: 75-85.
-
(1996)
Bone
, vol.18
, pp. 75-85
-
-
Lin, J.H.1
-
32
-
-
22244432201
-
Pharmacokinetics/pharmacodynamics of bisphosphonates: Use for optimisation of intermittent therapy for osteoporosis
-
Cremers SC, Pillai G, Papapoulos SE, 2005 Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44: 551-570.
-
(2005)
Clin Pharmacokinet
, vol.44
, pp. 551-570
-
-
Cremers, S.C.1
Pillai, G.2
Papapoulos, S.E.3
-
33
-
-
36549010158
-
Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates
-
Kimmel DB, 2007 Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86: 1022-1033.
-
(2007)
J Dent Res
, vol.86
, pp. 1022-1033
-
-
Kimmel, D.B.1
-
34
-
-
0030766092
-
Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis
-
Khan SA, Kanis JA, Vasikaran S, et al, 1997 Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12: 1700-1707.
-
(1997)
J Bone Miner Res
, vol.12
, pp. 1700-1707
-
-
Khan, S.A.1
Kanis, J.A.2
Vasikaran, S.3
-
35
-
-
33847734705
-
Prolonged bisphosphonate release after treatment in children
-
Papapoulos SE, Cremers SC, 2007 Prolonged bisphosphonate release after treatment in children. N Engl J Med 356: 1075-1076.
-
(2007)
N Engl J Med
, vol.356
, pp. 1075-1076
-
-
Papapoulos, S.E.1
Cremers, S.C.2
-
36
-
-
80052283962
-
Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover
-
Peris P, Torra M, Olivares V, et al, 2011 Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone 49: 706-709.
-
(2011)
Bone
, vol.49
, pp. 706-709
-
-
Peris, P.1
Torra, M.2
Olivares, V.3
-
37
-
-
0041331740
-
Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal
-
Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C, 2003 Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33: 301-307.
-
(2003)
Bone
, vol.33
, pp. 301-307
-
-
Bagger, Y.Z.1
Tanko, L.B.2
Alexandersen, P.3
Ravn, P.4
Christiansen, C.5
-
38
-
-
0028806469
-
Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate
-
Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE, 1995 Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 80: 3465-3468.
-
(1995)
J Clin Endocrinol Metab
, vol.80
, pp. 3465-3468
-
-
Landman, J.O.1
Hamdy, N.A.2
Pauwels, E.K.3
Papapoulos, S.E.4
-
39
-
-
12144289279
-
Ten years' experience with alendronate for osteoporosis in postmenopausal women
-
Bone HG, Hosking D, Devogelaer JP, et al, 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189-1199.
-
(2004)
N Engl J Med
, vol.350
, pp. 1189-1199
-
-
Bone, H.G.1
Hosking, D.2
Devogelaer, J.P.3
-
40
-
-
33845890326
-
Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial
-
Black DM, Schwartz AV, Ensrud KE, et al, 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927-2938.
-
(2006)
JAMA
, vol.296
, pp. 2927-2938
-
-
Black, D.M.1
Schwartz, A.V.2
Ensrud, K.E.3
-
41
-
-
38849130073
-
Fracture risk remains reduced one year after discontinuation of risedronate
-
Watts NB, Chines A, Olszynski WP, et al, 2008 Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19: 365-672.
-
(2008)
Osteoporos Int
, vol.19
, pp. 365-672
-
-
Watts, N.B.1
Chines, A.2
Olszynski, W.P.3
-
42
-
-
84855512805
-
-
Paschalidis eds, Athens
-
Guyton A 1992. Medical Physiology, Paschalidis eds, Athens; pp, 1205-1207.
-
(1992)
Medical Physiology
, pp. 1205-1207
-
-
Guyton, A.1
-
43
-
-
64049104797
-
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial
-
Reid DM, Devogelaer JP, Saag K, et al, 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373: 1253-1263.
-
(2009)
Lancet
, vol.373
, pp. 1253-1263
-
-
Reid, D.M.1
Devogelaer, J.P.2
Saag, K.3
|